Evelo Biosciences

| homepage = }}Evelo Biosciences, formerly known as "Evelo Therapeutics", is a biotechnology company that is discovering and developing the therapeutic modality of monoclonal microbials for treatment of cancer, inflammatory and autoimmune diseases. It focuses on therapeutic potential of orally delivered naturally occurring microbes to modulate immunological and biological effects in a human body. The company is headquartered in Cambridge, Massachusetts, U.S.

History

The company was founded in 2015, by Flagship Pioneering, a venture capital company that initially invested $35 million to launch Evelo Therapeutics. Noubar Afeyan is the chairman of Evelo Biosciences and the co-founder of Flagship Pioneering.

In April 2016, Evelo and University of Chicago have entered into an exclusive agreement to develop microbiome-based cancer immunotherapies.

On July 12, 2016, the company announced a merger with Epiva Therapeutics, holding a combined 50 patents and applications in medical research. Both companies agreed to retain the name Evelo Biosciences.

In July 2017, Evelo Biosciences acquired $50 million in a series B round led by Flagship Pioneering, with additional funding from Google Ventures, Celgene, Alexandria Venture Investments, and Mayo Clinic.

In November 2017, the company has collaborated with Mayo Clinic to develop microbiome drugs to treat inflammatory and neuroinflammatory diseases.